Compare Aurora Cannabis Inc (ACB) vs Upstart Holdings Inc (UPST) Price & Performance

Aurora Cannabis (ACB) trades at $2.99, up 0.34% with a bullish technical signal despite mixed earnings. The company achieved record annual medical cannabis revenue growth of 18% YoY to $288.6 million in FY2026, but faces margin pressure from Canadian reimbursement changes. Recent Q1 2027 earnings beat expectations with $0.04 EPS versus -$0.13 estimate, though revenue declined to $67.6 million. The stock shows strong institutional support with shareholder approval of board measures and EU-GMP certification for international expansion.

ACB presents a high-risk opportunity with significant volatility. While international medical cannabis growth and operational improvements provide upside potential, persistent net losses, negative ROE/ROA, and Canadian market challenges create substantial headwinds. Analyst consensus remains cautious with only 21% buy ratings, reflecting concerns about profitability timeline and competitive pressures in the evolving cannabis sector.

Upstart (UPST) trades at $31.09, up 4.64% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth of 42% year-over-year and a return to GAAP profitability, with loan originations surging 50%. However, it has missed EPS expectations for three consecutive quarters. The stock is supported by a consensus analyst price target of $47.20, implying significant upside, but faces headwinds from high interest rates and competitive pressures.

The outlook is mixed: strong loan growth and AI-driven underwriting improvements offer growth potential, but recent earnings misses, a high P/E ratio of 59.79, and negative operating cash flow in 2025 pose risks. Investor sentiment is cautiously optimistic, with 45% of analysts rating it a Buy, though volatility from macroeconomic factors remains a key concern for shareholders.